We provide clients with expert assistance in clinical trial and drug development, protocol design, review of clinical trial data and management of adverse hematologic events.

Welcome to Catlett Hematology Advisory Services


Catlett Hematology Advisory Services (CHAS) offers consultations for a variety of issues and works closely with its clients to find answers to crucial questions, develop promising therapies, and achieve successful outcomes.

Our consulting company maintains a high level of expertise in the evolving knowledge of basic science, potential therapeutic targets, and advances in the diagnosis and treatment of hematologic diseases.

Dr. Joseph Catlett, founding and managing member of Catlett Hematology Advisory Services, a limited liability company, has over thirty years of experience in the research and treatment of both benign and malignant hematologic disorders. 

CHAS is strategically located in the District of Columbia, close to the U. S. Food and Drug Administration, the National Institutes of Health, and several major academic centers. 

Hematologic research and drug development

With over thirty years of clinical experience, CHAS offers hematologic expertise for the following:

  • Guidance during design and conduct of clinical trials

  • Protocol review for appropriateness of objectives, clinically meaningful endpoints and monitoring during treatment

  • Review of data for hematologic safety signals

  • Advice regarding adverse event detection and mitigation strategies

  • Assistance with medico-legal issues (CHAS does not offer ‘expert witness’ services)

  • Input for forensic cases 

Gene editing

Consulting Services

CHAS offers consultations on a wide range of hematologic issues and concerns.

Blood rheology

Clinical Experience

We have an extensive background in benign and malignant hematologic disorders.

Pathologic review of blood and bone marrow smears

About Us

Joseph P. Catlett, MD, FACP, is the Founder of Catlett Hematology Advisory Services.

Located in Washington, DC, close to the U. S. Food and Drug Administration, the National Institutes of Health, and regional academic centers.